|
|
||||||||||
|
J Am Coll Cardiol, 2001; 38:1070-1077 © 2001 by the American College of Cardiology Foundation |
,2
,2
,2
* St. Louis University Health Sciences Center, St. Louis, Missouri, USA
Montreal Heart Institute, Montreal, Quebec, Canada
Washington Heart Center, Washington, DC, USA
Med. Universitatsklinik, Herzchirurgische Klinik, Luebeck, Germany
|| Aventis Pharmaceuticals, Inc., Bridgewater, New Jersey, USA
Manuscript received February 9, 2001; revised manuscript received May 29, 2001, accepted June 15, 2001.
Reprint requests and correspondence: Dr. Bernard R. Chaitman, St. Louis University Health Sciences Center, Division of Cardiology (15th Floor), 3635 Vista Avenue at Grand Boulevard, P.O. Box 15250, St. Louis, Missouri 63110-0250
chaitman{at}slu.edu
OBJECTIVES
We sought to determine if elevated cardiac serum biomarkers after coronary artery bypass graft surgery (CABG) are associated with increased medium-term mortality and to identify patients that may benefit from better postoperative myocardial protection.
BACKGROUND
The relationship between the magnitude of cardiac serum protein elevation and subsequent mortality after CABG is not well defined, partly because of the lack of large, prospectively studied patient cohorts in whom postoperative elevations of cardiac serum markers have been correlated to medium- and long-term mortality.
METHODS
The GUARD during Ischemia Against Necrosis (GUARDIAN) study enrolled 2,918 patients assigned to the entry category of CABG and considered as high risk for myocardial necrosis. Creatine kinase-myocardial band (CK-MB) isoenzyme measurements were obtained at baseline and at 8, 12, 16 and 24 h after CABG.
RESULTS
The unadjusted six-month mortality rates were 3.4%, 5.8%, 7.8% and 20.2% for patients with a postoperative peak CK-MB ratio (peak CK-MB value/upper limits of normal [ULN] for laboratory test) of <5,
5 to <10,
10 to <20 and
20 ULN, respectively (p < 0.0001). The relationship remained statistically significant after adjustment for ejection fraction, congestive heart failure, cerebrovascular disease, peripheral vascular disease, cardiac arrhythmias and the method of cardioplegia delivery. Receiver operating characteristic curve analysis revealed an area under the curve of 0.648 (p < 0.001); the optimal cut-point to predict six-month mortality ranged from 5 to 10 ULN.
CONCLUSIONS
Progressive elevation of the CK-MB ratio in clinically high-risk patients is associated with significant elevations of medium-term mortality after CABG. Strategies to afford myocardial protection both during CABG and in the postoperative phase may serve to improve the clinical outcome.
| ||||||||||||||||||||
This article has been cited by other articles:
![]() |
MEND-CABG II Investigators* Efficacy and Safety of Pyridoxal 5'-Phosphate (MC-1) in High-Risk Patients Undergoing Coronary Artery Bypass Graft Surgery: The MEND-CABG II Randomized Clinical Trial JAMA, April 16, 2008; 299(15): 1777 - 1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Mentzer Jr, C. Bartels, R. Bolli, S. Boyce, G. D. Buckberg, B. Chaitman, A. Haverich, J. Knight, P. Menasche, M. L. Myers, et al. Sodium-Hydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study Ann. Thorac. Surg., April 1, 2008; 85(4): 1261 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Luo, B. Li, R. Chen, R. Huang, and G. Lin Effect of ischemic postconditioning in adult valve replacement Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 203 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Mentzer Jr, M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2008; 3(2008): 443 - 464. [Full Text] |
||||
![]() |
E. Gongora and T. M. Sundt III Myocardial Revascularization with Cardiopulmonary Bypass Card. Surg. Adult, January 1, 2008; 3(2008): 599 - 632. [Full Text] |
||||
![]() |
K. Thygesen, J. S. Alpert, H. D. White, and on behalf of the Joint ESC/ACCF/AHA/WHF Task Force Universal Definition of Myocardial Infarction J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2173 - 2195. [Full Text] [PDF] |
||||
![]() |
K. Thygesen, J. S. Alpert, H. D. White, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force, TASK FORCE MEMBERS: Chairpersons: Kristian Thygese, Biomarker Group: Allan S. Jaffe, Coordinator (USA), ECG Group: Bernard Chaitman, Co-ordinator (USA), P, Imaging Group: Richard Underwood, Coordinator (UK), Intervention Group: Jean-Pierre Bassand, Co-ordina, Clinical Investigation Group: Paul W. Armstrong, C, et al. Universal Definition of Myocardial Infarction Circulation, November 27, 2007; 116(22): 2634 - 2653. [Full Text] [PDF] |
||||
![]() |
Task Force Members, K. Thygesen, J. S. Alpert, H. D. White, Biomarker Group, A. S. Jaffe, F. S. Apple, M. Galvani, H. A. Katus, L. K. Newby, et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Eur. Heart J., October 2, 2007; 28(20): 2525 - 2538. [Full Text] [PDF] |
||||
![]() |
J.-C. Tardif, M. Carrier, D. E. Kandzari, R. Emery, R. Cote, T. Heinonen, M. Zettler, V. Hasselblad, M.-C. Guertin, R. A. Harrington, et al. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: Results of the MEND-CABG randomized study J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1604 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Mahaffey, M. T. Roe, R. Kilaru, J. H. Alexander, F. Van de Werf, R. M. Califf, M. L. Simoons, E. J. Topol, and R. A. Harrington Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials Eur. Heart J., February 2, 2007; 28(4): 425 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Croal, G. S. Hillis, P. H. Gibson, M. T. Fazal, H. El-Shafei, G. Gibson, R. R. Jeffrey, K. G. Buchan, D. West, and B. H. Cuthbertson Relationship Between Postoperative Cardiac Troponin I Levels and Outcome of Cardiac Surgery Circulation, October 3, 2006; 114(14): 1468 - 1475. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Haverich, S. K. Shernan, J. H. Levy, J. C. Chen, M. Carrier, K. M. Taylor, F. Van de Werf, M. F. Newman, P. X. Adams, T. G. Todaro, et al. Pexelizumab Reduces Death and Myocardial Infarction in Higher Risk Cardiac Surgical Patients Ann. Thorac. Surg., August 1, 2006; 82(2): 486 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.V. Podgoreanu, W.D. White, R.W. Morris, J.P. Mathew, M. Stafford-Smith, I.J. Welsby, H.P. Grocott, C.A. Milano, M.F. Newman, D.A. Schwinn, et al. Inflammatory Gene Polymorphisms and Risk of Postoperative Myocardial Infarction After Cardiac Surgery Circulation, July 4, 2006; 114(1_suppl): I-275 - I-281. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Y Leung and J K French End points in clinical trials: are they moving the goalposts? Heart, July 1, 2006; 92(7): 870 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Carrier, P. Menasche, J.H. Levy, M.F. Newman, K.M. Taylor, A. Haverich, J.C. Chen, S.K. Shernan, F. Van de Werf, M. van der Laan, et al. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery J. Thorac. Cardiovasc. Surg., February 1, 2006; 131(2): 352 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Paparella, G. Cappabianca, G. Visicchio, A. Galeone, A. Marzovillo, N. Gallo, C. Memmola, and L. d. L. T. Schinosa Cardiac Troponin I Release After Coronary Artery Bypass Grafting Operation: Effects on Operative and Midterm Survival Ann. Thorac. Surg., November 1, 2005; 80(5): 1758 - 1764. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Bulow, C Klein, I Kuehn, R Hollweck, S G Nekolla, K Schreiber, F Haas, J Bohm, B Schnackenburg, R Lange, et al. Cardiac magnetic resonance imaging: long term reproducibility of the late enhancement signal in patients with chronic coronary artery disease Heart, September 1, 2005; 91(9): 1158 - 1163. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Bybee, B. D. Powell, U. Valeti, A. G. Rosales, S. L. Kopecky, C. Mullany, and R. S. Wright Preoperative Aspirin Therapy Is Associated With Improved Postoperative Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Circulation, August 30, 2005; 112(9_suppl): I-286 - I-292. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Engoren, R. H. Habib, A. Zacharias, T. A. Schwann, C. J. Riordan, S. J. Durham, and A. Shah The association of elevated creatine kinase-myocardial band on mortality after coronary artery bypass grafting surgery is time and magnitude limited Eur. J. Cardiothorac. Surg., July 1, 2005; 28(1): 114 - 119. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ramsay, S. Shernan, J. Fitch, P. Finnegan, T. Todaro, T. Filloon, and N. A. Nussmeier Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves J. Thorac. Cardiovasc. Surg., February 1, 2005; 129(2): 300 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pandey, A. D. Grayson, D. M. Pullan, B. M. Fabri, and W. C. Dihmis Total arterial revascularisation: effect of avoiding cardiopulmonary bypass on in-hospital mortality and morbidity in a propensity-matched cohort Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 94 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. S. Jonjev, S. Nicin, V. Mujovic, L. Petrovic, and N. Radovanovic Prostacyclin Reduces Incidence of Myocardial Damage After Coronary Endarterectomy Ann. Thorac. Surg., October 1, 2004; 78(4): 1299 - 1303. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Shernan, J. C. K. Fitch, N. A. Nussmeier, J. C. Chen, S. A. Rollins, C. F. Mojcik, K. J. Malloy, T. G. Todaro, T. Filloon, S. W. Boyce, et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass Ann. Thorac. Surg., March 1, 2004; 77(3): 942 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Riedel, J. Gal, G. Ellis, P. J. Marangos, A. W. Fox, and D. Royston Myocardial Protection Using Fructose-1,6-Diphosphate During Coronary Artery Bypass Graft Surgery: A Randomized, Placebo-Controlled Clinical Trial Anesth. Analg., January 1, 2004; 98(1): 20 - 29. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Gavard, B. R. Chaitman, S. Sakai, K. Stocke, N. Danchin, L. Erhardt, R. Gallo, E. Chi, A. Jessel, and P. Theroux Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome: results from the GUARDIAN trial J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 807 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Boyce, C. Bartels, R. Bolli, B. Chaitman, J. C. Chen, E. Chi, A. Jessel, D. Kereiakes, J. Knight, L. Thulin, et al. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 420 - 427. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P Marso, B. D Bliven, J. A House, G. F Muehlebach, and A.M. Borkon Myonecrosis following isolated coronary artery bypass grafting is common and associated with an increased risk of long-term mortality Eur. Heart J., July 2, 2003; 24(14): 1323 - 1328. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Mentzer Jr, R. D. Lasley, A. Jessel, and M. Karmazyn Intracellular sodium hydrogen exchange inhibition and clinical myocardial protection Ann. Thorac. Surg., February 1, 2003; 75(2): S700 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2003; 2(2003): 413 - 438. [Full Text] |
||||
![]() |
S. J. Brener, B. W. Lytle, J. P. Schneider, S. G. Ellis, and E. J. Topol Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1961 - 1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Nass and L. A. Fleisher Diagnosing Perioperative Myocardial Infarction in Cardioth oracic and Vascular Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2002; 6(3): 219 - 227. [Abstract] [PDF] |
||||
![]() |
C. P. Cannon, A. Battler, R. G. Brindis, J. L. Cox, S. G. Ellis, N. R. Every, J. T. Flaherty, R. A. Harrington, H. M. Krumholz, M. L. Simoons, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee) Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American College of Emergency Physicians, American Heart Association, Cardiac Society of Australia & New Zealand, National Heart Foundation of Australia, Society for Cardiac Angiography and Interventions, and the Taiwan Society of Cardiology J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2114 - 2130. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |